Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia

Citations Over TimeTop 10% of 2011 papers

Abstract

The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.

Related Papers

• → Prevalence and pattern of diabetic dyslipidemia in Indian type 2 diabetic patients(2009)42 cited
• → Dyslipidemia Among Newly Diagnosed Hypertensives: Pattern and Clinical Correlates(2010)34 cited
• → Cross-sectional study of pattern of Dyslipidemia and Prevalence of Atherogenic Diabetic Dyslipidemia in newly detected Diabetic patients(2019)4 cited
• Analysis of factors associated with dyslipidemia of some check-up crowd from Zhengzhou(2009)
• Analysis of dyslipidemia for staffs at government departments of some towns in Wuling mountains(2013)